Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

2026-03-11 - 15:23

SPRING, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc. in Spring, Texas, announces collaborative publication of data from preclinical studies with scientists at The University of Texas MD Anderson Cancer Center demonstrating effectiveness of the retinoid X receptor (RXR) agonist compound IRX4204 in models of prevention of estrogen receptor-negative and triple-negative breast cancers in three different genetically predisposed mouse models. Read More